Pipeline
CU04
CU04
Low-molecular immuno-cancer drugs that can be administered alone
| Sortation | content |
|---|---|
| CU04 | CBP/EP300 bromodomain Inhibitor |
| Indication | Cancer |
| Mechanism of Action |
|
| Efficacy |
• Low molecular weight candidate that creates medicinal effects in patients who are resistant to existing targeted anticancer agents • Developed candidates that enhance anticancer effect by inhibiting Treg cells through administration • Developed candidate that decreases c-MYC gene expression • Developed orally administered drug that can be provided at a lower cost |